Theratechnologies Insider-Eigentum
Was ist das Insider-Eigentum von Theratechnologies?
Insider-Eigentum von Theratechnologies, Inc. ist 1.22%
Was ist die Definition von Insider-Eigentum?
Das Insider-Eigentum wird berechnet als die Gesamtzahl der Aktien, die sich im Besitz von Insidern (Anteilseignern, die mehr als 5% der Gesellschaft oder eines leitenden Angestellten oder Direktors der Gesellschaft besitzen), dividiert durch die Gesamtzahl der ausstehenden Aktien.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider-Eigentum von Unternehmen in Health Care Sektor auf TSX im Vergleich zu Theratechnologies
Was macht Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Unternehmen mit insider-eigentum ähnlich Theratechnologies
- Community System hat Insider-Eigentum von 1.22%
- Principal hat Insider-Eigentum von 1.22%
- Principal Inc hat Insider-Eigentum von 1.22%
- Houghton Mifflin Harcourt Co hat Insider-Eigentum von 1.22%
- Real Estate Credit Investments hat Insider-Eigentum von 1.22%
- Eagle Point Credit Inc hat Insider-Eigentum von 1.22%
- Theratechnologies hat Insider-Eigentum von 1.22%
- Theratechnologies hat Insider-Eigentum von 1.22%
- RPM International hat Insider-Eigentum von 1.23%
- Takeda Pharmaceutical Co hat Insider-Eigentum von 1.23%
- Myers Industries hat Insider-Eigentum von 1.23%
- Devro Plc hat Insider-Eigentum von 1.24%
- J Sainsbury Plc hat Insider-Eigentum von 1.24%